About Organovo Holdings (NASDAQ:ONVO)
Organovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:ONVO
- CUSIP: N/A
- Web: www.organovo.com
Capitalization:- Market Cap: $157.06 million
- Outstanding Shares: 106,123,000
Average Prices:- 50 Day Moving Avg: $2.04
- 200 Day Moving Avg: $2.47
- 52 Week Range: $1.32 - $4.08
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.47
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $4.33 million
- Price / Sales: 37.25
- Book Value: $0.54 per share
- Price / Book: 2.81
Profitability:- EBITDA: ($38,770,000.00)
- Net Margins: -918.97%
- Return on Equity: -65.49%
- Return on Assets: -60.15%
Debt:- Current Ratio: 15.72%
- Quick Ratio: 15.60%
Misc:- Average Volume: 1.05 million shs.
- Beta: 3.02
- Short Ratio: 21.68
Frequently Asked Questions for Organovo Holdings (NASDAQ:ONVO)
What is Organovo Holdings' stock symbol?
Organovo Holdings trades on the NASDAQ under the ticker symbol "ONVO."
How were Organovo Holdings' earnings last quarter?
Organovo Holdings, Inc. (NASDAQ:ONVO) released its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). The firm had revenue of $0.99 million for the quarter, compared to analyst estimates of $0.92 million. Organovo Holdings had a negative return on equity of 65.49% and a negative net margin of 918.97%. The business's quarterly revenue was up 11.1% compared to the same quarter last year. View Organovo Holdings' Earnings History.
When will Organovo Holdings make its next earnings announcement?
Where is Organovo Holdings' stock going? Where will Organovo Holdings' stock price be in 2017?
4 brokers have issued 1-year price objectives for Organovo Holdings' shares. Their forecasts range from $3.75 to $15.00. On average, they expect Organovo Holdings' share price to reach $6.94 in the next twelve months. View Analyst Ratings for Organovo Holdings.
Who are some of Organovo Holdings' key competitors?
Some companies that are related to Organovo Holdings include Corvus Pharmaceuticals (CRVS), Puretech Health PLC (PRTC), Novavax (NVAX), NewLink Genetics Corporation (NLNK), Curis (CRIS), Nabriva Therapeutics AG (NBRV), Horizon Discovery Group PLC (HZD), Chromadex Corp (CDXC), Compugen (CGEN), Merrimack Pharmaceuticals (MACK), Pluristem Therapeutics (PSTI), Silence Therapeutics plc (SLN), CASI Pharmaceuticals (CASI), Advaxis (ADXS), OncoMed Pharmaceuticals (OMED), Infinity Pharmaceuticals (INFI), Asterias Biotherapeutics (AST) and Asterias Biotherapeutics (AST).
Who are Organovo Holdings' key executives?
Organovo Holdings' management team includes the folowing people:
- Taylor J. Crouch, President, Chief Executive Officer
- Eric Michael David M.D. J.D., Executive Vice President - Pre-Clinical Development, Chief Strategy Officer
- Sharon Collins Presnell Ph.D., Chief Scientific Officer
- Jennifer Kinsbruner Bush J.D., Compliance Officer, General Counsel, Corporate Secretary
- Paul Gallant, General Manager
- Richard Maroun, Director
- Robert F. Baltera Jr., Lead Independent Director
- James T. Glover, Independent Director
- Richard A. Heyman Ph.D., Independent Director
- Tamar D. Howson, Independent Director
How do I buy Organovo Holdings stock?
Shares of Organovo Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Organovo Holdings' stock price today?
One share of Organovo Holdings stock can currently be purchased for approximately $1.52.
MarketBeat Community Rating for Organovo Holdings (NASDAQ ONVO)MarketBeat's community ratings are surveys of what our community members think about Organovo Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Organovo Holdings (NASDAQ:ONVO) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 4 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $6.94 (356.41% upside) |
Consensus Price Target History for Organovo Holdings (NASDAQ:ONVO)
Analysts' Ratings History for Organovo Holdings (NASDAQ:ONVO)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/26/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $4.00 | High |  |
| 6/9/2017 | Evercore ISI | Reiterated Rating | Outperform | $4.00 -> $3.75 | Low | |
| 1/25/2017 | Raymond James Financial, Inc. | Initiated Coverage | Outperform | $5.00 | N/A | |
| 12/15/2016 | BTIG Research | Initiated Coverage | Buy | $15.00 | N/A | |
(Data available from 10/18/2015 forward)
Earnings History for Organovo Holdings (NASDAQ:ONVO)Earnings History by Quarter for Organovo Holdings (NASDAQ ONVO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/1/2017 | | ($0.10) | | | | | N/A | |
| 8/9/2017 | Q1 2018 | ($0.10) | ($0.10) | $0.92 million | $0.99 million | View | Listen | |
| 6/7/2017 | Q4 2017 | ($0.11) | ($0.10) | $0.76 million | $0.80 million | View | Listen | |
| 2/9/2017 | Q3 2017 | ($0.10) | ($0.09) | $1.40 million | $1.15 million | View | Listen | |
| 11/3/2016 | Q217 | ($0.11) | ($0.10) | $0.50 million | $1.38 million | View | Listen | |
| 8/4/2016 | Q1 | ($0.10) | ($0.09) | $0.30 million | $0.89 million | View | Listen | |
| 6/9/2016 | Q4 | ($0.11) | ($0.09) | $0.10 million | $0.55 million | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Organovo Holdings (NASDAQ:ONVO)2018 EPS Consensus Estimate: ($0.10)
2019 EPS Consensus Estimate: ($0.32)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q3 2018 | 1 | ($0.10) | ($0.10) | ($0.10) |
| Q1 2019 | 1 | ($0.09) | ($0.09) | ($0.09) |
| Q2 2019 | 1 | ($0.09) | ($0.09) | ($0.09) |
| Q3 2019 | 1 | ($0.07) | ($0.07) | ($0.07) |
| Q4 2019 | 1 | ($0.07) | ($0.07) | ($0.07) |
(Data provided by Zacks Investment Research)
Dividend History for Organovo Holdings (NASDAQ:ONVO)
No dividend announcements for this company have been tracked by MarketBeat.com
Headline Trends for Organovo Holdings (NASDAQ:ONVO)
Latest Headlines for Organovo Holdings (NASDAQ:ONVO)
| Source: |
|
| Date | Headline |
|---|
 | Organovo Holdings, Inc. (ONVO) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - October 15 at 11:32 PM |
| Critical Review: Organovo Holdings (ONVO) & Its Rivals
www.americanbankingnews.com - October 13 at 2:20 PM |
 | ETFs with exposure to Organovo Holdings, Inc. : October 9, 2017
finance.yahoo.com - October 9 at 8:48 PM |
| Q3 2018 EPS Estimates for Organovo Holdings, Inc. Decreased by Analyst (ONVO)
www.americanbankingnews.com - October 9 at 5:56 AM |
| Organovo Holdings, Inc. (ONVO) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - October 8 at 9:00 AM |
| Organovo Holdings, Inc. :ONVO-US: Earnings Analysis: Q1, 2018 By the Numbers : October 6, 2017
finance.yahoo.com - October 6 at 9:11 AM |
 | Organovo to cut 13% of workforce, announces preliminary revenues - Seeking Alpha
seekingalpha.com - October 5 at 1:56 PM |
| Organovo Holdings, Inc. (ONVO) Receives "Buy" Rating from Jefferies Group LLC
www.americanbankingnews.com - September 26 at 8:56 PM |
| The Competitive Case For Organovo Holdings - Seeking Alpha
seekingalpha.com - September 22 at 7:31 AM |
| Jefferies Group LLC Reiterates "Buy" Rating for Organovo Holdings, Inc. (ONVO)
www.americanbankingnews.com - September 14 at 7:16 PM |
| Organovo Holdings, Inc. (ONVO) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 13 at 9:34 AM |
 | BRIEF-Organovo says Keith Murphy submitted resignation as chairman of board
www.reuters.com - August 29 at 6:23 AM |
 | Global 3D Bioprinting Market Outlook to 2022 - Focus on Technology, Application and Materials - Research and Markets
www.businesswire.com - August 26 at 8:01 AM |
 | Organovo Sponsors Pioneering Research With Amgen and Medikine in Critical Areas of Liver and Kidney Disease - Nasdaq
www.nasdaq.com - August 23 at 9:49 AM |
| Organovo Sponsors Pioneering Research With Amgen and Medikine in Critical Areas of Liver and Kidney Disease
finance.yahoo.com - August 23 at 9:49 AM |
| Organovo Holdings, Inc. (ONVO) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - August 19 at 9:02 AM |
| Q3 2018 Earnings Forecast for Organovo Holdings, Inc. (NASDAQ:ONVO) Issued By Jefferies Group
www.americanbankingnews.com - August 14 at 7:54 AM |
| ETFs with exposure to Organovo Holdings, Inc. : August 11, 2017
finance.yahoo.com - August 12 at 6:36 AM |
| Organovo Holdings, Inc. (ONVO) Announces Earnings Results, Hits Estimates
www.americanbankingnews.com - August 11 at 9:58 PM |
| Organovo Holdings Revenue Is Growing at a Snail's Pace Compared With Prior Quarters
finance.yahoo.com - August 11 at 7:16 AM |
| Investor Network: Organovo Holdings, Inc. to Host Earnings Call
finance.yahoo.com - August 10 at 6:29 AM |
| Organovo Announces Fiscal First-Quarter 2018 Results; Company Affirms Full-Year Fiscal 2018 Outlook
finance.yahoo.com - August 10 at 6:29 AM |
| Edited Transcript of ONVO earnings conference call or presentation 9-Aug-17 9:00pm GMT
finance.yahoo.com - August 10 at 6:29 AM |
| Organovo reports 1Q loss
finance.yahoo.com - August 10 at 6:29 AM |
 | Organovo (ONVO) Secures 3-Yr $1.7M Grants from National Institutes of Health to Study Liver Disease
www.streetinsider.com - August 1 at 5:34 AM |
| Organovo (ONVO) Secures 3-Yr $1.7M Grants from National Institutes of Health to Study Liver Disease - StreetInsider.com
www.streetinsider.com - August 1 at 12:31 AM |
| Organovo and UC San Diego Receive $1.7 Million Grant From National Institutes of Health to Study Liver Disease
finance.yahoo.com - August 1 at 12:31 AM |
| ETFs with exposure to Organovo Holdings, Inc. : July 31, 2017
finance.yahoo.com - August 1 at 12:31 AM |
| Organovo Holdings, Inc. (ONVO) Short Interest Down 7.2% in July
www.americanbankingnews.com - July 28 at 1:24 AM |
| Organovo Holdings, Inc. (NASDAQ:ONVO) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - July 27 at 5:55 PM |
| $880,000.00 in Sales Expected for Organovo Holdings, Inc. (NASDAQ:ONVO) This Quarter
www.americanbankingnews.com - July 20 at 11:44 AM |
| Organovo Announces Release Date for Fiscal First-Quarter 2018 Financial Results
finance.yahoo.com - July 19 at 12:55 AM |
 | How Risky Is Organovo Holdings, Inc.?
www.fool.com - July 18 at 4:13 PM |
| Organovo - Going The Right Direction - Seeking Alpha
seekingalpha.com - July 15 at 7:12 AM |
| ETFs with exposure to Organovo Holdings, Inc. : July 13, 2017
finance.yahoo.com - July 14 at 7:09 AM |
| Here's Why Organovo Holdings Inc Fell 10.5% in June
finance.yahoo.com - July 11 at 6:24 AM |
| ETFs with exposure to Organovo Holdings, Inc. : July 3, 2017
finance.yahoo.com - July 4 at 2:59 AM |
| 3 Reasons Organovo Holdings, Inc. Stock Could Fall Even More
www.fool.com - June 22 at 4:32 PM |
 | Organovo to Present at Jefferies Healthcare Conference - GlobeNewswire (press release)
www.globenewswire.com - June 5 at 7:39 PM |
 | Research Reports Initiation on Medical Labs Stocks -- Organovo, DexCom, Quest ...
www.prnewswire.com - May 9 at 11:17 AM |
 | Clearside Biomedical, Inc. Announces Completion Of Patient Enrollment In Phase 1/2 Open Label Clinical Trial Of CLS-TA In Diabetic Macular Edema
www.thestreet.com - April 20 at 9:07 AM |
| Organovo Holdings CEO Leaves: Should Investors Be Worried? - Motley Fool
www.fool.com - April 14 at 8:03 AM |
| What's Next for Organovo Holdings Inc.? - Motley Fool
www.fool.com - April 12 at 7:59 PM |
 | 2 inmates charged with killing 4 in South Carolina prison - USA TODAY
www.usatoday.com - April 8 at 6:17 PM |
 | Trump Shifts Course on Egypt, Praising Its Authoritarian Leader - New York Times
www.nytimes.com - April 3 at 6:24 PM |
| China Learns How to Get Trump's Ear: Through Jared Kushner - New York Times
www.nytimes.com - April 2 at 10:53 AM |
| Senate panel to vote on Supreme Court nominee Neil Gorsuch - USA TODAY
www.usatoday.com - April 2 at 10:53 AM |
 | Michael Flynn left Russian speaking fees off initial financial disclosures - CNN
www.cnn.com - April 2 at 10:53 AM |
 | Part of I-85 collapses in Atlanta after massive fire
www.foxnews.com - March 31 at 12:21 AM |
 | White House adviser Jared Kushner to appear before Senate Intelligence Committee
abcnews.go.com - March 27 at 9:55 AM |
Organovo Holdings (ONVO) Chart for Wednesday, October, 18, 2017
